ReviewNanomedicine (London, England)2025
Exploring the potential of repurposed deferoxamine: bridging challenges and novel formulation opportunities.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Chronic Hypoxia-Induced Reprogramming of Smooth Muscle Cells: Insights into Transcription Factors, Cellular Stresses, and Therapeutic Implications.Biomedicines · 2026Article
- Comparative evaluation of microfluidic-synthesized nano-niosomes versus liposomal and micro-niosomal deferoxamine in murine iron overload models.Research in pharmaceutical sciences · 2026Article
- Iron and Copper Homeostasis in Cardiometabolic Disease: Therapeutic Potential of Chelators.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Traditional Chinese Medicine and Ferroptosis in Alzheimer's Disease: A Potential Therapeutic Approach.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the FDA approval of deferoxamine mesylate (Desferal) in 1968, the characteristic low plasma half-life, low plasma protein binding (PB), constrained volume of distribution (Vd), and variety of adverse effects made the dosing, bioavailability, and patient compliance as the main hurdle for clinical application of Deferoxamine (DFO). Nevertheless, these pharmacokinetic and pharmacodynamic constraints have been lessened by recent developments in novel drug carrier systems, which has resulted in an increased acceptance of DFO. The effective use of this drug in the treatment of Alzheimer, Parkinson, cancer, wound healing, and ferroptosis has further increased its clinical importance. According to our literature search on various reputed databases such as ScienceDirect, Nature, Wiley, ACS, etc. accumulating results of last 18 years, there has been a significant increase in the overall number of studies conducted on various novel formulations and strategies regarding DFO e.g. polymeric nanoparticles, micelles, nanofibers, conjugates, photothermal therapy, etc. Clinical trial applications found on clinicaltrials.gov have doubled since 2020, and patent applications found on Google Patent have climbed by 320% since 2011. These results demonstrate DFO's versatility and its potential for usage not just in traditional applications but also as a repurposed therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.